argenx NV ADR (ARGX)vsCybin Inc. Common Stock (HELP)
ARGX
argenx NV ADR
$1,058.90
+1.13%
HEALTHCARE · Cap: $64.66B
HELP
Cybin Inc. Common Stock
$13.24
-2.86%
HEALTHCARE · Cap: $860.65M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
HELP
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$2398.58
Current Price
$1058.90
$1339.68 discount
Intrinsic value data unavailable for HELP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 196.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : HELP
The strongest argument for HELP centers on Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : HELP
The primary concerns for HELP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while HELP is a value play — different risk/reward profiles.
HELP carries more volatility with a beta of 0.56 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (71/100 vs 23/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Cybin Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company is headquartered in Toronto, Canada.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?